AVDR - Avedro, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Avedro, Inc.

201 Jones Road
Waltham, MA 02451
United States

IndustryMedical Devices
Full Time Employees122

Key Executives

NameTitlePayExercisedYear Born
Dr. Reza ZadnoPres & CEO676.7kN/A1955
Dr. Rajesh K. RajpalChief Medical Officer & Member of Advisory Board393.15kN/A1963
Mr. James SchuermannChief Bus. Officer321.78kN/A1968
Mr. Joseph E. GilliamCFO, Sr. VP of Corp. Devel. & DirectorN/AN/A1976
Mr. Sujal N. BhalakiaVP of OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Avedro, Inc., an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations. Its Avedro Corneal Remodeling platform treats corneal ectatic disorders and corrects refractive conditions; and KXL system in combination with Photrexa drug formulations used for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Avedro sells its products primarily to ophthalmologists, hospitals, and ambulatory surgery centers through a direct sales force in the United States, as well as through medical device distributors internationally. The company was formerly known as ThermalVision, Inc. and changed its name to Avedro, Inc. in October 2005. Avedro, Inc. was incorporated in 2002 and is headquartered in Waltham, Massachusetts. As of November 21, 2019, Avedro, Inc. operates as a subsidiary of Glaukos Corporation.

Corporate Governance

Avedro, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.